Today: 8 February 2026
Subscribe
Browse Category

Cannabis Industry News 23 November 2025 - 9 January 2026

Tilray Brands (TLRY) stock jumps in premarket after record $218 mln quarter and net cash turn

Tilray Brands (TLRY) stock jumps in premarket after record $218 mln quarter and net cash turn

Tilray shares jumped nearly 9% to $9.95 in premarket trading after reporting fiscal Q2 revenue of $217.5 million and a narrowed net loss of $43.5 million. The company reaffirmed its full-year adjusted profit target and said it moved to a net cash position. Gross margin slipped, and craft beer sales remained under pressure. Traders are watching if the gains hold at the open.
9 January 2026
··
Canopy Growth (CGC) Stock on Dec. 24, 2025: Schedule III Executive Order, MTL Cannabis Deal, and the Latest Forecasts

Canopy Growth (CGC) Stock on Dec. 24, 2025: Schedule III Executive Order, MTL Cannabis Deal, and the Latest Forecasts

Canopy Growth shares closed at $1.40 on Dec. 23, up 6.06%, after heavy trading and sharp swings throughout December. The volatility followed a Dec. 18 White House executive order directing marijuana rescheduling from Schedule I to III. Trading volume spiked to over 216 million shares on Dec. 18, with implied volatility near 143%. U.S. exchanges operated a shortened session on Dec. 24.
24 December 2025
····
Tilray Brands (TLRY) Stock News Today: Cannabis Rescheduling, Earnings Date, Reverse Split, and Analyst Forecasts (Dec. 24, 2025)

Tilray Brands (TLRY) Stock News Today: Cannabis Rescheduling, Earnings Date, Reverse Split, and Analyst Forecasts (Dec. 24, 2025)

Tilray Brands shares traded near $10.53 on December 24, 2025, following sharp gains in the second half of the year. President Donald Trump signed an executive order on December 18 to begin the process of reclassifying marijuana from Schedule I to Schedule III. The move sparked volatility across cannabis stocks, with prices swinging as investors weighed the potential impact. The order does not legalize cannabis but directs federal agencies to review its status.
24 December 2025
··
Tilray Brands (TLRY) Stock News Today: Trump Cannabis Rescheduling Reports Fuel Volatility, Fresh Forecasts and Key Levels (Dec. 17, 2025)

Tilray Brands (TLRY) Stock News Today: Trump Cannabis Rescheduling Reports Fuel Volatility, Fresh Forecasts and Key Levels (Dec. 17, 2025)

Tilray Brands shares jumped 27% to $13.94 on December 17, 2025, amid reports President Donald Trump may soon sign an executive order to reclassify marijuana at the federal level. The stock swung between $10.32 and $14.54 during the session. Reuters and NBC News cited sources saying the move could come this week. No final decision has been made, according to a White House spokesperson.
17 December 2025
···
S&P/TSX Composite Today: Oil Slips Toward $60, Cannabis Surges, and Macklem’s Speech Looms for After-the-Bell Trade (Dec. 16, 2025)

S&P/TSX Composite Today: Oil Slips Toward $60, Cannabis Surges, and Macklem’s Speech Looms for After-the-Bell Trade (Dec. 16, 2025)

Canada’s S&P/TSX Composite index fell about 0.5% to 31,324 in late-morning trading Tuesday, led by a 3% drop in energy stocks as oil prices slid below $60 on Russia–Ukraine peace hopes. Weak Chinese economic data and oversupply concerns added pressure. Cannabis stocks rose after U.S. President Trump floated marijuana reclassification. Organigram reported record results, boosting sector sentiment.
16 December 2025
··
Tilray Brands (TLRY) Stock News Today: Cannabis Rally Cools as Trump Schedule III Speculation Fuels Volatility

Tilray Brands (TLRY) Stock News Today: Cannabis Rally Cools as Trump Schedule III Speculation Fuels Volatility

Tilray shares fell about 7% to $11.30 in late trading December 15, reversing some of last week’s 65% rally. The surge and pullback followed reports that Donald Trump may push to reclassify cannabis to Schedule III, but the White House signaled no decision is final. Uncertainty over timing and scope cooled investor appetite across the cannabis sector.
15 December 2025
··
Tilray Stock Surges as Trump Schedule III Buzz Collides With New Vape Launch and Reverse Split Fallout

Tilray Stock Surges as Trump Schedule III Buzz Collides With New Vape Launch and Reverse Split Fallout

Tilray Brands shares surged December 15 as global cannabis stocks rallied on reports that Donald Trump may push to reclassify marijuana as a Schedule III drug. The move, which would ease federal restrictions but stop short of legalization, fueled investor optimism over potential tax and banking benefits for the industry. Tilray also completed a 1-for-10 reverse stock split and reported momentum in its Canadian portfolio.
15 December 2025
····
Canopy Growth Corporation Stock (CGC) Surges on Trump Marijuana Rescheduling Reports: Latest News, Forecasts, and What Comes Next (Dec. 15, 2025)

Canopy Growth Corporation Stock (CGC) Surges on Trump Marijuana Rescheduling Reports: Latest News, Forecasts, and What Comes Next (Dec. 15, 2025)

Canopy Growth shares surged as much as 17.9% in early European trading Monday, extending Friday’s 54% jump, after reports that President Trump may reclassify marijuana as a Schedule III drug. Trading volume spiked, with speculation focused on potential U.S. federal reform and its impact on cannabis industry taxes. No final decision has been confirmed by the White House.
15 December 2025
··
Tilray Brands (TLRY) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Tilray Brands (TLRY) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Tilray Brands shares surged 44% to $12.15 Friday after reports that President Trump may direct agencies to reclassify marijuana as a Schedule III drug. Volume reached 84.2 million shares, with prices swinging between $10.32 and $13.85. The move follows Tilray’s 1-for-10 reverse stock split effective Dec. 2. Timing of any federal action remains uncertain.
14 December 2025
···
Tilray Brands (TLRY) Stock Jumps on Marijuana Rescheduling Buzz: This Week’s Move, Latest News, and Week-Ahead Outlook (Updated Dec. 12, 2025)

Tilray Brands (TLRY) Stock Jumps on Marijuana Rescheduling Buzz: This Week’s Move, Latest News, and Week-Ahead Outlook (Updated Dec. 12, 2025)

Updated: Friday, Dec. 12, 2025 (after U.S. market close)Meta description: Tilray (TLRY) surged this week as cannabis stocks spiked on reports Trump may push marijuana rescheduling. Here’s what happened and what to watch next week. Tilray Brands, Inc. (NASDAQ: TLRY) delivered one of the cannabis sector’s most dramatic weekly moves, culminating in a surge on Friday, December 12, as traders reacted to fresh reporting that President Donald Trump could soon take steps aimed at loosening federal marijuana restrictions. By the close on Dec. 12, TLRY finished at $12.15, up 44.13% on the day, after trading between $10.28 and $12.41. Volume
13 December 2025
··
Top Stock Gainers Today (Dec. 12, 2025, 12:30 p.m. ET): cbdMD, Canopy Growth, Tilray Lead a Cannabis-Fueled Rally

Top Stock Gainers Today (Dec. 12, 2025, 12:30 p.m. ET): cbdMD, Canopy Growth, Tilray Lead a Cannabis-Fueled Rally

Here are the biggest US stock market gainers at midday on Dec. 12, 2025—plus what’s driving the moves, from cannabis policy headlines to earnings reports and SEC filings. StockAnalysis+2Reuters+2 At 12:30 p.m. ET on Friday, December 12, 2025, the US stock market is showing a familiar split screen: broad indexes are lower, led by weakness in tech and semiconductors, while a handful of headline-driven pockets—especially cannabis-related names and a few earnings movers—are posting outsized gains. On a percentage basis across US-listed stocks, many of the day’s top gainers are small-cap and micro-cap companies, where relatively modest flows (and, at times, trading halts or low liquidity) can translate
12 December 2025
····
Cronos Group Inc (CRON) Stock Surges as US Marijuana Rescheduling Buzz Returns — Latest News, Forecasts, and Key Catalysts (Dec. 12, 2025)

Cronos Group Inc (CRON) Stock Surges as US Marijuana Rescheduling Buzz Returns — Latest News, Forecasts, and Key Catalysts (Dec. 12, 2025)

December 12, 2025 — Cronos Group Inc. (NASDAQ: CRON , TSX: CRON ) is back in the spotlight after cannabis stocks jumped broadly into early trading on reports that the Trump administration could pursue a major easing of federal marijuana restrictions — specifically, a push to reclassify marijuana from Schedule I to Schedule III .Reuters+ 1 For Cronos investors, today’s move is not happening in a vacuum. The stock entered December with fresh momentum after the company announced a strategic acquisition in the Netherlands , a deal that management says would give Cronos the #1 market share within Europe’s largest
12 December 2025
··
Canopy Growth Corporation Stock (CGC) Jumps on Trump Marijuana Rescheduling Report — News, Forecasts, and What Investors Are Watching (Dec. 12, 2025)

Canopy Growth Corporation Stock (CGC) Jumps on Trump Marijuana Rescheduling Report — News, Forecasts, and What Investors Are Watching (Dec. 12, 2025)

Canopy Growth Corporation stock (NASDAQ: CGC ; TSX: WEED ) is in the spotlight on Friday, December 12, 2025 , after a fresh wave of US federal policy speculation sent cannabis names sharply higher in premarket trading. The immediate catalyst: a report that President Donald Trump is expected to push for a major easing of federal marijuana restrictions—specifically, directing agencies to reclassify marijuana as a Schedule III drug . That headline quickly rippled through US-listed cannabis stocks, with Canopy Growth among the notable movers.Reuters+ 1 Below is a detailed round-up of today’s key news , today’s market reaction , and
12 December 2025
····
Tilray Brands (TLRY) Stock Jumps on Trump Marijuana Rescheduling Report: Latest News, Forecasts, and Analyst Views (Dec. 12, 2025)

Tilray Brands (TLRY) Stock Jumps on Trump Marijuana Rescheduling Report: Latest News, Forecasts, and Analyst Views (Dec. 12, 2025)

Tilray Brands (NASDAQ: TLRY) is surging as cannabis stocks rally on fresh U.S. rescheduling headlines. Here’s what’s driving TLRY, what analysts forecast, and what to watch next. Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) is back in the spotlight on Friday, December 12, 2025, after a sharp move higher in extended-hours trading and premarket action alongside a broader rally in cannabis-linked equities. The immediate catalyst is political: a report that President Donald Trump is expected to push the federal government to loosen marijuana restrictions by directing agencies toward reclassifying marijuana as a Schedule III substance—a shift that could materially change
12 December 2025
···
US Stock Market Premarket Top Gainers Today (Dec. 12, 2025): Lululemon Surges, Cannabis Stocks Rally, Mitek and Quanex Jump

US Stock Market Premarket Top Gainers Today (Dec. 12, 2025): Lululemon Surges, Cannabis Stocks Rally, Mitek and Quanex Jump

Updated: Friday, December 12, 2025 — 6:00 a.m. ET SEO summary: Here are the biggest US stock market premarket gainers today (NYSE/Nasdaq) and the news driving them, including Lululemon’s earnings and CEO transition, a cannabis-stock surge tied to marijuana rescheduling headlines, and earnings-driven jumps in Mitek and Quanex. Nasdaq+4StockAnalysis+4Reuters+4 US stock futures were mixed early Friday, with investors balancing a post-Fed backdrop against renewed questions around big-tech AI spending after Oracle’s latest move and broader positioning into year-end. Reuters Below is a detailed look at the top premarket gainers as of about 6:00 a.m. ET, plus the headlines, forecasts, and analyst takes circulating on 12/12/2025. Top premarket stock gainers right now (as of ~6:00 a.m. ET) These are the leading percentage gainers in
12 December 2025
·············
Tilray Brands (TLRY) Soars After Reverse Stock Split and Cannabis Bill Hopes: Stock Forecast, Price Targets and 2026 Outlook

Tilray Brands (TLRY) Soars After Reverse Stock Split and Cannabis Bill Hopes: Stock Forecast, Price Targets and 2026 Outlook

As of December 10, 2025 Tilray stock rebounds 12% after brutal selling Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) just reminded investors how violently cannabis stocks can move. On Tuesday, December 9, 2025, TLRY jumped about 12.4% to close around $8.09, sharply outperforming a flat broader market. Trading volume topped 8.6 million shares, above the 50‑day average of roughly 7.8 million. Even after that rally, Tilray’s share price is still about 65% below its 52‑week high of $23.20, reached on October 9. MarketWatch+1 The surge followed weeks of heavy selling. On December 3, the stock fell 8.4% to $7.06, marking
10 December 2025
···
Aurora Cannabis (ACB) Stock on December 7, 2025: Australia Deal, Q2 2026 Earnings and What Forecasts Say Next

Aurora Cannabis (ACB) Stock on December 7, 2025: Australia Deal, Q2 2026 Earnings and What Forecasts Say Next

Aurora Cannabis Inc. (NASDAQ: ACB; TSX: ACB) is ending 2025 in a very different place from where it started. After years of restructuring, the company has become a highly focused global medical cannabis business, with new partnerships in Australia, expanding operations in Europe, and back‑to‑back quarters of record medical revenue. As of the latest trading sessions before December 7, 2025, ACB’s U.S.-listed shares trade around US$4.60, while the TSX listing changes hands near C$6.39, giving the company a market value in roughly the US$260–280 million range. Investing.com+2Stock Titan+2 Here’s a deep dive into the latest news, earnings, forecasts and analyses
7 December 2025
··
Canopy Growth (CGC) Stock Outlook December 2025: Debt Prepayment, Lawsuit Pressure and a High‑Risk Turnaround

Canopy Growth (CGC) Stock Outlook December 2025: Debt Prepayment, Lawsuit Pressure and a High‑Risk Turnaround

December 6, 2025 Canopy Growth Stock Snapshot as of December 6, 2025 Canopy Growth Corp (NASDAQ: CGC, TSX: WEED) remains one of the most volatile names in global cannabis — and 2025 has been no exception. In other words, CGC is bouncing off its lows but still priced like a distressed turnaround. Q2 FY2026 Earnings: Margins Improve, Losses Narrow Canopy’s second quarter of fiscal 2026 (three months ended September 30, 2025) was the first real proof that its years‑long restructuring might be gaining traction. According to the company’s official earnings release and independent summaries: Canopy Growth+1 Fintool’s recap notes that,
6 December 2025
··
Tilray Stock Today, November 23, 2025: TLRY Under $1 as AI Trading Signals, Hemp Rules and Big Holders Collide

Tilray Stock Today, November 23, 2025: TLRY Under $1 as AI Trading Signals, Hemp Rules and Big Holders Collide

Tilray Brands stock (NASDAQ: TLRY; TSX: TLRY) is back in the spotlight this Sunday, November 23, 2025, for all the reasons that make cannabis names both fascinating and stressful to follow:the share price has slipped back under $1, new AI-driven trading plans dropped this morning, a fresh “millionaire maker” think-piece is circulating, and regulators are pulling the sector in opposite directions. Here’s a full breakdown of everything new on Tilray today, plus the key numbers, fundamentals, and risks traders are weighing right now. Tilray stock price snapshot for November 23, 2025 Because U.S. markets are closed today (Sunday), the latest
23 November 2025
··
1 2

Stock Market Today

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

8 February 2026
Tower Semiconductor shares rose 7.7% to $139.04 Friday after announcing a collaboration with Nvidia on AI data-center networking. The stock touched $141 intraday and gained another 1% after hours. Investors await Tower’s Feb. 11 earnings for details on its silicon photonics work. No financial terms or shipment timeline were disclosed.
Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Longsys disclosed new guarantees for a 100 million yuan Hong Kong loan and a $9 million Brazil credit line, bringing its total approved guarantee quota to 11 billion yuan and outstanding guarantees to 5.81 billion yuan. The company said all guarantees are for consolidated subsidiaries and within approved limits. Shares closed at 288 yuan Friday, down 1.6%. China inflation and credit data are due this week.
MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop